You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SGLT2 inhibition

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

SGLT2 Inhibition in Heart Failure

Recruiting
  • Heart Failure
  • Sodium-glucose cotransporter 2 inhibitor
  • Belfast, United Kingdom
    Belfast Health and Social Care Trust
Nov 15, 2023

Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure Trial

Not yet recruiting
  • Heart Failure NYHA Class II
  • +2 more
    • (no location specified)
    May 22, 2023

    Obesity, Metabolic Syndrome Trial in Nashville (Empagliflozin 25 MG, Placebo)

    Not yet recruiting
    • Obesity
    • Metabolic Syndrome
    • Empagliflozin 25 MG
    • Placebo
    • Nashville, Tennessee
      Vanderbilt University Medical Center
    Jul 24, 2023

    Immunoglobulin A Nephropathy Trial in Denver (Sparsentan)

    Not yet recruiting
    • Immunoglobulin A Nephropathy
    • Denver, Colorado
      Travere Investigational Site
    May 12, 2023

    Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas Trial in Saint Louis (Dapagliflozin, BIOSENSE meters)

    Completed
    Has Results
    • Pancreas Cancer
    • +2 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Dec 20, 2022

    Type 2 Diabetes, Hypertension Trial in New Orleans (Dapagliflozin, Sulfonylurea, Placebo)

    Completed
    Has Results
    • Type 2 Diabetes
    • Hypertension
    • New Orleans, Louisiana
      Tulane University
    Oct 5, 2022

    Type2diabetes, PreDiabetes, Renal Failure Trial in Duesseldorf, Heidelberg (Dapagliflozin (Forxiga®), Placebo matching

    Not yet recruiting
    • Type2diabetes
    • +2 more
    • Dapagliflozin (Forxiga®)
    • +2 more
    • Duesseldorf, Germany
    • +1 more
    Sep 18, 2023

    Type 2 Diabetes, Myocardial Fibrosis, Myocardial Inflammation Trial in Seattle (dapagliflozin, Placebo)

    Completed
    • Type 2 Diabetes Mellitus
    • +2 more
    • Seattle, Washington
      University of Washington
    Jan 9, 2023

    Kidney Failure, Hemodialysis, Diabetes, Type 2 Trial (Dapagliflozin 10 MG, Placebo)

    Not yet recruiting
    • Kidney Failure
    • +4 more
    • Dapagliflozin 10 MG
    • Placebo
    • (no location specified)
    Aug 23, 2022

    Acute Kidney Injury, Kidney Failure, Sodium Glucose Cotransporter-2 Inhibitors Trial in Newtown (SGLT2 inhibitor or matched )

    Not yet recruiting
    • Acute Kidney Injury
    • +2 more
    • SGLT2 inhibitor or matched placebo
    • Newtown, New South Wales, Australia
      The George Institute for Global Health
    Jul 19, 2022

    Type 2 Diabetes, Diabetic Kidney Disease Trial in Aurora, Boston, Ann Arbor (canagliflozin, Aminohippurate Sodium Inj 20%)

    Recruiting
    • Type 2 Diabetes
    • Diabetic Kidney Disease
    • Aurora, Colorado
    • +3 more
    Aug 17, 2022

    Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors Trial in Toronto

    Not yet recruiting
    • Peritoneal Dialysis Complication
    • +4 more
    • Empagliflozin 25 MG
    • Toronto, Ontario, Canada
      Toronto General Hospital
    Jan 27, 2023

    Heart Attack, Enlarged Heart Trial in Minneapolis (Dapagliflozin, Placebo)

    Recruiting
    • Heart Attack
    • Enlarged Heart
    • Minneapolis, Minnesota
      Minneapolis Heart Institute Foundation
    Aug 4, 2022

    Prostate Cancer, Cancer of Prostate Trial in Saint Louis (Dapagliflozin, BIOSENSE Meter)

    Not yet recruiting
    • Prostate Cancer
    • Cancer of Prostate
    • Saint Louis, Missouri
      Washington University School of Medicine
    Nov 19, 2021

    Aging Trial in San Antonio (Dapagliflozin 10 mg, Nutritional counseling)

    Recruiting
    • Aging
    • Dapagliflozin 10 mg
    • Nutritional counseling
    • San Antonio, Texas
    • +1 more
    Dec 23, 2021

    Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis

    Recruiting
    • Chronic Renal Failure
    • Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis
    • Dapagliflozin 10mg Tab
    • +5 more
    • Marseille, France
    • +1 more
    May 23, 2023

    Obesity, Pre-diabetes Trial in Nashville (Empagliflozin 25 MG)

    Completed
    • Obesity
    • Pre-diabetes
    • Empagliflozin 25 MG
    • Nashville, Tennessee
      Vanderbilt University Medical Center
    Feb 12, 2022

    Type 2 Diabetes Trial in Amsterdam (Empagliflozin 25 MG, Benzbromaron, Empagliflozin 25 MG + benzbromarone 100 mg)

    Completed
    • Type 2 Diabetes
    • Empagliflozin 25 MG
    • +2 more
    • Amsterdam, Noord-Holland, Netherlands
      VU University Medical Center
    Jan 13, 2022

    Diabetes, Type 1 Trial in Bern (Forxiga 10mg, Placebo)

    Recruiting
    • Diabetes Mellitus, Type 1
    • Forxiga 10mg
    • Placebo
    • Bern, Switzerland
      Department of Diabetes, Endocrinology, Nutritional Medicine and
    Nov 7, 2022

    Metabolic Syndrome, Type 2 Diabetes, Obesity Trial in Perth (Empagliflozin Oral Tablet [Jardiance], Placebo Oral Tablet)

    Recruiting
    • Metabolic Syndrome
    • +2 more
    • Empagliflozin Oral Tablet [Jardiance]
    • Placebo Oral Tablet
    • Perth, Western Australia, Australia
      Royal Perth Hospital
    Sep 23, 2021

    Heart Failure, Type 2 Diabetes Trial in Dundee (Empagliflozin 25mg, Placebo oral capsule, Frusemide)

    Completed
    Has Results
    • Heart Failure
    • Type 2 Diabetes Mellitus
    • Empagliflozin 25mg
    • +2 more
    • Dundee, Angus, United Kingdom
      University of Dundee, Ninewells Hospital and Medical School
    Jun 22, 2021

    Obesity, Non-diabetic Chronic Kidney Disease Trial (Empagliflozin 10 MG)

    Withdrawn
    • Obesity
    • Non-diabetic Chronic Kidney Disease
    • Empagliflozin 10 MG
    • (no location specified)
    Sep 6, 2021

    Diabetes, Type 2 Trial in San Antonio (Placebo, Exenatide, Dapagliflozin)

    Active, not recruiting
    • Diabetes Mellitus, Type 2
    • Placebo
    • +3 more
    • San Antonio, Texas
      University Health System Texas Diabetic Institute
    Apr 28, 2022

    Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor Trial in Netherlands (Dapagliflozin 10 MG Oral

    Not yet recruiting
    • Acute Kidney Injury
    • +2 more
    • Dapagliflozin 10 MG Oral Tablet [Farxiga]
    • Placebo
    • Amsterdam, Netherlands
    • +5 more
    Oct 18, 2022

    Type 2 Diabetes, Obesity Trial in Amsterdam (Dapagliflozin 10mg, Exenatide, exenatide)

    Completed
    • Type 2 Diabetes Mellitus
    • Obesity
    • Dapagliflozin 10mg
    • +3 more
    • Amsterdam, Noord-Holland, Netherlands
      Amsterdam UMC, location VU Medical Center
    Jun 8, 2021